Last Price
1.74
Today's Change
-0.04 (2.24%)
Day's Change
1.73 - 1.82
Trading Volume
353,193
Overview
Market Cap
89 Million
Shares Outstanding
51 Million
Avg Volume
208,967
Avg Price (50 Days)
1.55
Avg Price (200 Days)
1.67
PE Ratio
-1.79
EPS
-0.97
Earnings Announcement
07-Nov-2024
Previous Close
1.78
Open
1.82
Day's Range
1.735 - 1.82
Year Range
1.4 - 3.47
Trading Volume
353,193
Price Change Highlight
1 Day Change
-2.25%
5 Day Change
7.41%
1 Month Change
16.78%
3 Month Change
19.18%
6 Month Change
-19.44%
Ytd Change
-44.23%
1 Year Change
-6.45%
3 Year Change
-92.98%
5 Year Change
-95.36%
10 Year Change
-95.36%
Max Change
-95.36%
News and Blogs
No result.
Company Profile
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
12
Apps
Top Articles
1
CEO Morning Brief
Nvidia Rides AI Wave to Pass Apple as World’s Largest Company Again
2
3
CEO Morning Brief
Paramount Gives Up on Warner Bros Merger After Months of Talks
4
CEO Morning Brief
Global CEOs Confront New Era With Trump Win, Risk of Tariffs
5
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
